Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Pre-Mkt 02-06 06:29:57 EST

16.47

-0.83

-4.80%

High17.88	Low16.37	Vol2.50M
Open17.17	D1 Closing17.30	Amplitude8.73%
Mkt Cap2.51B	Tradable Cap1.93B	Total Shares152.67M
T/O41.92M	T/O Rate2.13%	Tradable Shares117.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":16.47,"timestamp":1770325200000,"preClose":17.3,"halted":0,"volume":2497306,"delay":0,"changeRate":-0.04797687861271687,"floatShares":117369033,"shares":152665188,"eps":-0.529487,"marketStatus":"Pre-Mkt","change":-0.83,"latestTime":"02-06 06:29:57 EST","open":17.17,"high":17.88,"low":16.37,"amount":41921738.901209995,"amplitude":0.087283,"askPrice":19.58,"askSize":100,"bidPrice":12.73,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.529487,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770388200000},"marketStatusCode":1,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":16.47,"postHourTrading":{"tag":"盘后","latestPrice":17.5,"preClose":16.47,"latestTime":"19:59 EST","volume":52322,"amount":877835.4607,"timestamp":1770339560690,"change":1.03,"changeRate":0.062538,"amplitude":0.073467},"volumeRatio":1.259533041331001,"impliedVol":0.8958,"impliedVolPercentile":0.56},"requestUrl":"/m/hq/s/ADPT","defaultTab":"news","newsList":[{"id":"2609580211","title":"Earnings Flash (ADPT) Adaptive Biotechnologies Posts Q4 Loss $0.09, vs. FactSet Est of $0.19 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609580211","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609580211?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:17","pubTimestamp":1770329864,"startTime":"0","endTime":"0","summary":"Earnings Flash (ADPT) Adaptive Biotechnologies Posts Q4 Loss $0.09, vs. FactSet Est of $0.19 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADPT"],"gpt_icon":0},{"id":"1121542652","title":"Stock Track | Adaptive Biotechnologies Soars 6.25% After-Hours on Strong Q4 Results and Positive Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1121542652","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121542652?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:50","pubTimestamp":1770328240,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"gpt_icon":0},{"id":"2609214581","title":"Adaptive Biotechnologies Q4 EPS $(0.09) Beats $(0.18) Estimate, Sales $71.681M Beat $59.391M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2609214581","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609214581?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:06","pubTimestamp":1770325589,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Q4 EPS $(0.09) Beats $(0.18) Estimate, Sales $71.681M Beat $59.391M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50431038/adaptive-biotechnologies-q4-eps-0-09-beats-0-18-estimate-sales-71-681m-beat-59-391m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adaptive Biotechnologies Q4 EPS $(0.09) Beats $(0.18) Estimate, Sales $71.681M Beat $59.391M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2609581480","title":"Adaptive meldet für das Gesamtjahr einen Nettoverlust von 159,49 Mio. USD, ein Anstieg um 169 Prozent","url":"https://stock-news.laohu8.com/highlight/detail?id=2609581480","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609581480?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:05","pubTimestamp":1770325558,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies hat die Finanzergebnisse für das vierte Quartal  und das Gesamtjahr 2025 verffentlicht. Im vierten Quartal wies das Unternehmen einen den Aktionren zurechenbaren Nettoverlust von 13,58 Mio. USD aus. Für das Gesamtjahr lag der Nettoverlust bei 59,50 Mio. USD. Das bereinigte EBITDA belief sich im vierten Quartal auf 4,14 Mio. USD, whrend für das Gesamtjahr ein bereinigtes EBITDA von 12,15 Mio. USD ausgewiesen wurde. Die Abschreibungen und Amortisationen betrugen im vierten Quartal 4,20 Mio. USD und im Gesamtjahr 17,83 Mio. USD. Die Zinsaufwendungen lagen im vierten Quartal bei 2,95 Mio. USD und im Gesamtjahr bei 11,78 Mio. USD. Die aktienbasierten Vergütungsaufwendungen beliefen sich auf 12,72 Mio. USD im vierten Quartal und 51,48 Mio. USD im Gesamtjahr. Das Eigenkapital der Aktionre zum Bilanzstichtag betrug 218,79 Mio. USD. Die gesamten Verbindlichkeiten und das Eigenkapital beliefen sich auf 512,74 Mio. USD. Adaptive Biotechnologies betont, dass das bereinigte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL6H8R3g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0314104364.USD","SG9999014039.USD","BK4112","SG9999014005.SGD","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4121","BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","ADPT","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2609810515","title":"BRIEF-Adaptive Biotechnologies Q4 EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2609810515","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609810515?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:05","pubTimestamp":1770325547,"startTime":"0","endTime":"0","summary":"Feb 05  - Adaptive Biotechnologies Q4 revenue USD 71.681 million vs. IBES estimate USD 59.4 million.Q4 adjusted EBITDA USD 4.1 million vs. IBES estimate USD -7.45 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nPLX6B59A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2609582132","title":"Adaptive Biotechnologies: Expects FY Revenue for Mrd Business to Be Between $255 Million - $265 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2609582132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609582132?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:05","pubTimestamp":1770325503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nPLX6B59A7:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2609582130","title":"Adaptive Biotechnologies: Expect FY Operating Expenses, Including Cost of Revenue, to Be Between $350 Mln - $360 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2609582130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609582130?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:05","pubTimestamp":1770325503,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nPLX6B59A7:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"1130889969","title":"Stock Track | Adaptive Biotechnologies Plunges 10.40% in Pre-Market on Earnings Anticipation","url":"https://stock-news.laohu8.com/highlight/detail?id=1130889969","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130889969?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:03","pubTimestamp":1770296629,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp (ADPT) experienced a significant pre-market plunge of 10.40% on Thursday, as traders reacted ahead of the company's scheduled quarterly earnings report.The sharp decline...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"gpt_icon":0},{"id":"2609637665","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2609637665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609637665?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:00","pubTimestamp":1770289200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Alpha & Omega                                   2Q      (.08)   4:01 PM. ·Blue Owl Cap                                     4Q       .22    7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABG","BBVA","ENR","CDP","CX","ARES","AFRM","ATR","CAH","EXPO","CC","COP","ARW","B","EHC","ASX","CLSK","CHYM","COTY","FCFS","CUZ","CI","BARK","EQR","ADPT","BLSH","CNO","CPT","AB","BYD","AGCO","COUR","ARWR","BMY","BYRN","EL","BTU","EMBC","BILL","CMS","AOSL","BCE","CMI","DLR","CARR","DOCS","BBD","GOOS"],"gpt_icon":1},{"id":"2609317244","title":"Adaptive Biotechnologies CEO Chad M. Robins Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609317244","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609317244?lang=en_us&edition=fundamental","pubTime":"2026-02-05 08:37","pubTimestamp":1770251866,"startTime":"0","endTime":"0","summary":"Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corporation, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL26Wf6q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CEO Chad M. Robins Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"1189396859","title":"Earning Preview: Adaptive Biotechnologies Corp’s revenue is expected to increase by 29.02%, and institutional views are cautiously optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=1189396859","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189396859?lang=en_us&edition=fundamental","pubTime":"2026-01-29 13:31","pubTimestamp":1769664686,"startTime":"0","endTime":"0","summary":"AbstractAdaptive Biotechnologies Corp will report fourth-quarter results on February 05, 2026 Post Market; this preview evaluates consensus expectations alongside recent operating trends to frame...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Adaptive Biotechnologies Corp’s revenue is expected to increase by 29.02%, and institutional views are cautiously optimistic","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT"],"gpt_icon":0},{"id":"2606758557","title":"Adaptive Biotechnologies to Participate in BTIG and TD Cowen Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2606758557","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606758557?lang=en_us&edition=fundamental","pubTime":"2026-01-28 05:05","pubTimestamp":1769547911,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corporation will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026. The company will also take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston, MA on Monday, March 2, 2026, at 11:50 a.m. Eastern Time. Live and archived webcasts of these sessions will be available on the Investors section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire  on January 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL6xMD0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","ADPT","LU0314104364.USD","BK4121"],"gpt_icon":0},{"id":"2606124282","title":"Adaptive Biotechnologies Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2606124282","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606124282?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:34","pubTimestamp":1769445240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 11:34 ET (16:34 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2605412024","title":"Adaptive Biotechnologies Corporation to Report Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2605412024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605412024?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:05","pubTimestamp":1769115920,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire  on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL9Cw12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","ADPT","BK4585","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014039.USD","BK4121","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2603623106","title":"CFO Kyle Piskel Reports Disposal of Adaptive Biotechnologies Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603623106","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603623106?lang=en_us&edition=fundamental","pubTime":"2026-01-15 08:18","pubTimestamp":1768436290,"startTime":"0","endTime":"0","summary":"Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corporation, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL7t8t9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Kyle Piskel Reports Disposal of Adaptive Biotechnologies Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2603333186","title":"What's Going On With Adaptive Biotechnologies Shares Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603333186","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603333186?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:40","pubTimestamp":1768315200,"startTime":"0","endTime":"0","summary":"Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/13/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/13/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2602548578","title":"Adaptive Biotechnologies Shares Rise on Preliminary Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548578","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548578?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:27","pubTimestamp":1768224420,"startTime":"0","endTime":"0","summary":"Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results.The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year.The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million.For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million.Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added.The company plans to release its complete fourth-quarter and full-y","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2602517332","title":"Adaptive Biotechnologies Shares up 11.4% Premarket After Co Announces Preliminary Q4, FY25 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517332?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:39","pubTimestamp":1768221567,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2602512209","title":"Adaptive Biotechnologies Corp - Preliminary Q4 Revenue $72 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512209?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7VVBLP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2602512279","title":"Press Release: Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512279","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512279?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":"SEATTLE, Jan. 12, 2026  -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.-- Total revenue for the fourth quarter and full year 2025 was approximately. $72 million and $277 million, representing an increase of 51% and 55%,-- MRD revenue for the fourth quarter and full year 2025 was approximately. $62 million and $212 million, representing an increase of 54% and 46%,respectively, over the corresponding periods in 2024. Excluding MRD. regulatory milestone revenue, MRD revenue for full year 2025 grew 45%. fourth quarter 2025 compared to the fourth quarter 2024 and ended the. year with approximately 105,600 tests delivered, up 39% compared to full","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":-0.1034},{"period":"1month","weight":0.0223},{"period":"3month","weight":0.1136},{"period":"6month","weight":0.35},{"period":"1year","weight":1.046},{"period":"ytd","weight":0.0142}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.030689},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104089},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.10078},{"month":5,"riseRate":0.5,"avgChangeRate":0.108472},{"month":6,"riseRate":0.833333,"avgChangeRate":0.100403},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.001043},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}